Azithromycin for mild-to-moderate COVID-19
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428482/ https://www.ncbi.nlm.nih.gov/pubmed/34509194 http://dx.doi.org/10.1016/S2213-2600(21)00379-9 |
_version_ | 1783750387619069952 |
---|---|
author | Patel, Jigar Berezowski, Ivan Abdelmonem, Ahmed Taylor, Dania Pourmand, Ali |
author_facet | Patel, Jigar Berezowski, Ivan Abdelmonem, Ahmed Taylor, Dania Pourmand, Ali |
author_sort | Patel, Jigar |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-8428482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84284822021-09-10 Azithromycin for mild-to-moderate COVID-19 Patel, Jigar Berezowski, Ivan Abdelmonem, Ahmed Taylor, Dania Pourmand, Ali Lancet Respir Med Correspondence Elsevier Ltd. 2021-10 2021-09-09 /pmc/articles/PMC8428482/ /pubmed/34509194 http://dx.doi.org/10.1016/S2213-2600(21)00379-9 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Correspondence Patel, Jigar Berezowski, Ivan Abdelmonem, Ahmed Taylor, Dania Pourmand, Ali Azithromycin for mild-to-moderate COVID-19 |
title | Azithromycin for mild-to-moderate COVID-19 |
title_full | Azithromycin for mild-to-moderate COVID-19 |
title_fullStr | Azithromycin for mild-to-moderate COVID-19 |
title_full_unstemmed | Azithromycin for mild-to-moderate COVID-19 |
title_short | Azithromycin for mild-to-moderate COVID-19 |
title_sort | azithromycin for mild-to-moderate covid-19 |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428482/ https://www.ncbi.nlm.nih.gov/pubmed/34509194 http://dx.doi.org/10.1016/S2213-2600(21)00379-9 |
work_keys_str_mv | AT pateljigar azithromycinformildtomoderatecovid19 AT berezowskiivan azithromycinformildtomoderatecovid19 AT abdelmonemahmed azithromycinformildtomoderatecovid19 AT taylordania azithromycinformildtomoderatecovid19 AT pourmandali azithromycinformildtomoderatecovid19 |